AUTHOR=Kunos Charles A. , Fabian Denise , Piecoro Dava W. , Napier Dana , Miller Rachel W. , Ueland Frederick R. 

TITLE=Human epidermal growth factor receptor 2 expression in women with uterine cervix adenocarcinoma from Appalachian Kentucky

JOURNAL=Frontiers in Oncology

VOLUME=13

YEAR=2023

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.948348

DOI=10.3389/fonc.2023.948348

ISSN=2234-943X

ABSTRACT=<sec><title>Introduction</title><p>High-risk human epidermal growth factor receptor 2 (HER2)-positive adenocarcinomas associate with early recurrence and death, prompting consideration of novel radiotherapeutic options like a trastuzumab-linked thorium-227 alpha-particle emitting radionuclide.</p></sec><sec><title>Methods</title><p>We conducted a retrospective pilot biomarker study of uterine cervix cancers among patients in Appalachian Kentucky, to characterize an exploitable triage biomarker like HER2 expression before starting a prospective phase 0 trial.</p></sec><sec><title>Results</title><p>Most (60%) adenocarcinomas showed HER2 cell-surface overexpression, whereas squamous cell carcinomas (4%) did not do so.</p></sec><sec><title>Discussion</title><p>Further validation tests of HER2 expression as a triage biomarker for radiopharmaceutical selection are warranted.</p></sec>